Compounds > pyrroles
Page last updated: 2024-08-18

pyrroles and pasireotide

pyrroles has been researched along with pasireotide in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bodei, L; Cinieri, S; de Braud, F; Delle Fave, G; Fazio, N; Lorizzo, K; Maiello, E; Orlando, L; Paganelli, G; Spada, F; Squadroni, M1
Igarashi, H; Ito, T; Jensen, RT; Takayanagi, R1
Boussaha, T; Lepere, C; Rougier, P; Taieb, J1
Ito, T; Jensen, RT; Lee, L1

Reviews

4 review(s) available for pyrroles and pasireotide

ArticleYear
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Neuroendocrine; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrroles; Receptors, Somatostatin; Sirolimus; Somatostatin; Sunitinib; Vascular Endothelial Growth Factor A

2010
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
    Fukuoka igaku zasshi = Hukuoka acta medica, 2012, Volume: 103, Issue:7

    Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immunosuppressive Agents; Indoles; Japan; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Somatostatin; Streptozocin; Sunitinib; Temozolomide

2012
Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:2

    Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bevacizumab; Clinical Trials as Topic; Digestive System Neoplasms; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2013
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:16

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pyrroles; Somatostatin; Sunitinib; Syndrome; Treatment Outcome

2016